Postprandial cholesterol metabolism: a clue to the impact of TM6SF2 rs58542926 variant on liver and cardiovascular disease in NAFLD?

This is the author's manuscript

Original Citation:

Availability:
This version is available http://hdl.handle.net/2318/1625474 since 2017-02-21T14:55:40Z

Terms of use:
Open Access
Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)
This is an author version of the contribution published on:

Questa è la versione dell’autore dell’opera:

Biochimica Clinica, 40, SS: S33-S34, 2016

The definitive version is available at:

La versione definitiva è disponibile alla URL:

Non Disponibile
POSTPRANDIAL CHOLESTEROL METABOLISM: A CLUE TO THE IMPACT OF TM6SF2 rs58542926 VARIANT ON LIVER AND CARDIOVASCULAR DISEASE IN NAFLD?
Roberto Gambino¹, Maurizio Cassader¹, Francesca Saba¹, Silvia Pinach¹, Natalina Alemanno¹, Giovanni Musso².

¹Department of Internal Medicine, University of Turin, Italy
²Gradenigo Hospital, Turin, Italy

Abstract

Background. Nonalcoholic fatty liver disease (NAFLD) encompasses a histological spectrum, ranging from simple steatosis to steatosis plus necroinflammation (NASH), which can be differentiated only by liver biopsy. Genetic factors contribute to the pathogenesis of NAFLD. Genetic variation in the transmembrane 6 superfamily member 2 protein (TM6SF2) at rs58542926 was shown to confer susceptibility to NAFLD.

Objective. We examined the impact of this polymorphism on postprandial lipoprotein subfractions and on postprandial changes in cytokeratin-18 fragments in normolipidemic biopsy-proven NAFLD patients and matched healthy controls.

Methods. Fifty-five nonobese, nondiabetic, normolipidemic biopsy-proven NASH patients and 55 age, sex, BMI-matched healthy controls underwent an oral fat load test, with measurement of plasma triglyceride-rich lipoprotein subfractions, total cholesterol, oxidized LDL, non-esterified fatty acids, E-selectin, ICAM, and cytokeratin-18 fragments.

Results. TM6SF2 T-allele carriers showed a lower postprandial triglyceridaemia and nefaemia, and a striking redistribution of cholesterol from smaller, more atherogenic VLDL2, LDL and oxLDL particles to larger VLDL1 subfractions than C-allele carriers. On multiple regression analysis, IAUC VLDL1-Cholesterol (VLDL1-Ch) during the oral fat load independently predicted NAFLD activity score (β=0.394, p=0.022), IAUC CK-18 (β=0.412, p=0.018) and fibrosis score (β=0.402, p=0.019), while IAUC oxLDL predicted circulating E-selectin (β=0.418, p=0.011) and ICAM-1 (β=0.451, p=0.012).

Conclusions. These findings may partially explain the impact of TM6SF2 C>T variant on liver injury and CVD risk in NAFLD. TM6SF2 C>T variant modulates dietary cholesterol fluxes, with T-allele diverting toxic cholesterol away from the vessel walls into the liver, thereby promoting liver injury. Consistently, circulating VLDL-Cholesterol closely correlated with hepatic cholesterol content, inflammation, fibrosis, and cell injury in NASH. If confirmed by larger follow-up studies, these findings may provide the rationale for evaluating approaches using cholesterol-lowering medications to alleviate hepatic cholesterol overload and liver injury in TM6SF2 T-allele carriers, irrespective of fasting blood cholesterol levels.